Navigation Links
New Cell Lines Cuts Down the Cost and Time in the Production of Flu Vaccine

Paul Coussens, a professor of animal science and microbiology and molecular genetics, and his colleagues from Michigan State University found that a new cell// line has the ability and potential for growing flu virus.

This is good news because it would result in the production of new human flu vaccines which is cheaper and produced in a shorter period of time.

He identified the new cell line while working on the Marek's disease which is a common chicken disease. This technique is very useful and is not time consuming when compared to the earlier procedure in which the virus strains were grown in fertilized chicken eggs. HepaLife Technologies Inc., a biotechnology company based in Vancouver, has licensed the technology from MSU and plans to produce cell culture-based flu vaccine. ‘We want to proceed as quickly as possible,’ said Harmel Rayat, president of HepaLife. ‘There's no time to waste. Sooner or later the avian flu virus will be in North America. It's not if, it's when.’

‘The recent highly virulent avian flu cases in Asia and fears about a pandemic have highlighted the problems with traditional influenza vaccine production methods, particularly the length of time to produce a new vaccine and the amount of vaccine that can be produced on short notice,’ said Coussens, who also is the director of the MSU Center for Animal Functional Genomics. Building on work done by graduate student Amin Abujoub and assistant professor David Reilly, Coussens and his collaborators found the cell line would grow almost every type of flu virus: avian, swine, equine and human.

In cell culture-based vaccine production, scientists infect cells with flu strains. Then they grow the virus in large vats or bioreactors. The virus is killed and purified to make the vaccine. Growing virus in cell culture could dramatically speed up vaccine production. For the past 50 years, flu vaccines have been made by injecting 11-day-old fertilized chicken eggs with a flu virus strain. The virus grows in the eggs and is then killed and purified to make the vaccine. Each egg is injected with only one virus strain (a typical flu vaccine contains three strains) and produces enough virus for one or two doses. This means that huge numbers of fertilized chicken eggs are needed – 270 million or more – to produce a sufficient vaccine supply for the United States.

The process is time consuming and inflexible because vaccine makers have to order eggs months ahead of time. If there are any problems with the eggs, such as infection by another virus, the entire lot of flu vaccine is lost. Plus, anyone with an egg allergy can't have the vaccine. ‘By growing cell culture-based flu virus, the cost and the time needed to produce the vaccine will be much lower,’ Coussens said. ‘We'll also be able to produce much more vaccine in a smaller space. And the virus that is grown is more pure. People with allergies to eggs are likely to benefit the most because they'll be able to have flu shots without the threat of allergic complications.’

Source: urekalert

Related medicine news :

1. Stem Cell Bank In UK Would Require 150 Embryo-Derived Stem Cell Lines
2. Increased Childhood Leukemia Risk If House Is Near Power Lines
3. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
4. Tea Found To Boost Insulin Production And Prevent Cataract
5. Conroy’s May Not Be Permitted To Resume Production Soo
6. Massive Production Of Bird Flu Vaccine To Be Initiated In China
7. Chugai Pharmaceutical To Initiate Domestic Production Of Bird Flu Vaccine
8. Coca Cola To Enhance Production Of Diet Coke
9. Natco Pharma Commences Production At Dehradun Unit
10. ABCB6 Is Key to Production of Heme in Hemoglobin
11. Drug Boosts Platelet Production, Reversing Immune Thrombocytopenic Purpura
Post Your Comments:

(Date:10/13/2015)... ... October 13, 2015 , ... CURE Media Group, ... announced a new partnership with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) ... lymphoma, their families and physicians. , “Waldenstrom’s Macroglobulinemia is a so-called ‘orphan ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... beverage companies in the United States, today announced the release of its limited ... and new Cranberry Cocktail Agua Fresca. All feature the unique flavor combinations and ...
(Date:10/13/2015)... ... October 13, 2015 , ... HealthAware , ... HIMSS’s Patient Engagement Summit . HealthAware is a technology company focused on ... and interventions via mobile devices that provide a framework for the development of ...
(Date:10/13/2015)... ... 2015 , ... ProText Kinetic Panel is a typography creation tool made for ... create energetic text animations in any layout without the use of keyframes. Using ProText ... and stylize the text. With intuitive on-screen controls, users can re-position and scale the ...
(Date:10/13/2015)... ... October 13, 2015 , ... Symposium Chairman, Dr. Rod J. ... Dallas Cosmetic Symposium to be held March 2nd and 3rd, 2016. The annual meeting, ... plastic surgeons and cosmetic physicians from around the world. , Key topics at this ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... COLLEGE PARK, Md. , Oct. 13, 2015 ... hubs is the biggest key to growing Baltimore ... to a report released today by the Maryland Technology ... already has many of the pieces in place to support ... Martha Connolly , director of Mtech Baltimore. "This study is ...
(Date:10/13/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... company serving the pharmaceutical, biotechnology, and medical device ... mobile version of OncoWuXi, the first App in ... models and data on the go.  The OncoWuXi ... time to identify relevant tumor models for use ...
(Date:10/13/2015)... Oct. 13, 2015 Health Gorilla ( ) ... Network – a secure platform for clinical data and ... interact about and manage healthcare in the US. The launch ... for a combined total of $4.4M raised to date, with ... True Ventures , Harris Barton , Orfin ...
Breaking Medicine Technology: